<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">772514</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2022.772514</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Pro-Angiogenesis Role of LINC00662 From Esophageal Squamous Cell Carcinoma Cells-Derived Extracellular Vehicles</article-title>
<alt-title alt-title-type="left-running-head">Li et al.</alt-title>
<alt-title alt-title-type="right-running-head">Pro-Angiogenesis Role of LINC00662 in ESCC</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Feng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niu</surname>
<given-names>Ren</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>ShaoLin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>FangChao</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dong</surname>
<given-names>Zefang</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Hao</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Shujun</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1471152/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>The Second Hospital of Hebei Medical University</institution>, <addr-line>Shijiazhuang</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Oncology</institution>, <institution>The Second Hospital of Hebei Medical University</institution>, <addr-line>Shijiazhuang</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Thoracic Surgery</institution>, <institution>The Second Hospital of Hebei Medical University</institution>, <addr-line>Shijiazhuang</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Institute of Precision Medicine and Pathology</institution>, <institution>Jinan University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/587108/overview">Eder Lilia Romero</ext-link>, National University of Quilmes, Argentina</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/911425/overview">Honglin Jin</ext-link>, Huazhong University of Science and Technology, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1410847/overview">Marie Morille</ext-link>, Institut de chimie mol&#xe9;culaire et des mat&#xe9;riaux Charles Gerhardt Montpellier (ICGM), France</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Shujun Li, <email>Lishujun1999@outlook.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Biomaterials, a section of the journal Frontiers in Bioengineering and Biotechnology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>01</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>772514</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>09</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>02</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Li, Niu, Gao, Zhao, Dong, Zhang and Li.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Li, Niu, Gao, Zhao, Dong, Zhang and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Objective:</bold> LINC00662 is oncogenic in some human cancers, but no much was revealed concerning to its specific action in tumor angiogenesis. Given that, our study investigated the role of LINC00662 from esophageal squamous cell carcinoma (ESCC) cells-derived extracellular vehicles (EVs) in angiogenesis through microRNA (miR)-195-5p/vascular endothelial growth factor A (VEGFA) axis.</p>
<p>
<bold>Methods:</bold> Clinical tissue samples were collected from patients with ESCC, in which LINC00662, miR-195-5p and VEGFA expression was analyzed. ESCC cells were transfected, from which EVs were isolated. Human umbilical vein endothelial cells (HUVECs) were co-cultured with the pretreated EVs. After that, viability, colony formation ability, invasion, migration and tube formation ability of HUVECs were observed. Tumor xenograft in nude mice was performed to detect the effect of LINC00662, miR-195-5p or EV specific inhibitor GW4869 on tumor development.</p>
<p>
<bold>Results:</bold> LINC00662 and VEGFA were upregulated while miR-195-5p was downregulated in the cancer tissue of patients with ESCC. EVs derived from ESCC cells promoted viability, colony formation ability, invasion and tube formation ability of HUVECs. Downregulation of LINC00662 or upregulation of miR-195-5p reversed the promotion of EVs derived from ESCC cells on the viability, colony formation ability, invasion and tube formation ability of HUVECs <italic>in vitro</italic> and <italic>in vivo</italic>. VEGFA overexpression reversed EVs carrying restored miR-195-5p induced effects on HUVECs <italic>in vitro</italic>.</p>
<p>
<bold>Conclusion:</bold> In summary, elevated LINC00662 transferred by ESCC cells-derived EVs induces angiogenesis through downregulating miR-195-5p and upregulating VEGFA.</p>
</abstract>
<kwd-group>
<kwd>esophageal squamous cell carcinoma</kwd>
<kwd>extracellular vehicles</kwd>
<kwd>LINC00662</kwd>
<kwd>microRNA-195-5p</kwd>
<kwd>vascular endothelial growth factor a</kwd>
</kwd-group>
<contract-sponsor id="cn001">Natural Science Foundation of Hebei Province<named-content content-type="fundref-id">10.13039/501100003787</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Esophageal squamous cell carcinoma (ESCC) is the main subtype of esophageal cancer (EC) which originates from the stratified squamous epithelium of the esophagus (<xref ref-type="bibr" rid="B29">Reichenbach et al., 2019</xref>). Because of repeated inflammation and mucosal damage of the esophagus, it is most often diagnosed by tissue biopsy during upper gastrointestinal endoscopy (<xref ref-type="bibr" rid="B2">Batra et al., 2019</xref>). ESCC mostly happens in late adulthood, and patients often experience symptoms such as dysphagia and weight loss (<xref ref-type="bibr" rid="B15">Lam, 2020</xref>). For advanced ESCC, cytotoxic agents (docetaxel, cisplatin and 5-FU), molecular-targeting therapy and immunotherapy are systematically applied to palliate symptoms and improve survival (<xref ref-type="bibr" rid="B12">Hirano and Kato, 2019</xref>). In tumor progression, tumor cells secrete high levels of pro-angiogenic factors, which contribute to the formation of abnormal vascular networks, leading to poor tumor perfusion (<xref ref-type="bibr" rid="B34">Viallard and Larriv&#xe9;e, 2017</xref>). Considering that, fighting against tumor angiogenesis may offer alternative therapeutic targets.</p>
<p>Extracellular vesicles (EVs) is a collective term involving in many subtypes of cell-released, membranous structures, named as exosomes, ectosomes, oncosomes, microvesicles, microparticles, apoptotic bodies, as well as many other names (<xref ref-type="bibr" rid="B33">Th&#xe9;ry et al., 2018</xref>). EV are cell membrane-derived vesicles, and cancer cells-derived EVs exert multiple roles in malignant progression, including metastasis and angiogenesis (<xref ref-type="bibr" rid="B13">Knox et al., 2020</xref>). Hypoxia-conditioned EVs from ESCC cells have been reported to induce tube formation of human umbilical vein endothelial cells (HUVECs) (<xref ref-type="bibr" rid="B25">Mao et al., 2019</xref>). As effective carriers, EVs can transfer nucleic acids including miRNA and long noncoding RNA into specific target cells, regulating cell function and tumor microenvironment (<xref ref-type="bibr" rid="B21">Lin et al., 2019</xref>). More and more studies have confirmed the pro-angiogenesis effect of cancer-derived EVs carrying tumor-promoting cargos (<xref ref-type="bibr" rid="B16">Lang et al., 2017</xref>; <xref ref-type="bibr" rid="B41">Zeng et al., 2018</xref>; <xref ref-type="bibr" rid="B10">He et al., 2019</xref>). LINC00662 refers to an oncogene in many cancers, which acts notoriously in the fields of tumor metastasis (<xref ref-type="bibr" rid="B6">Cheng B et al., 2020</xref>) and radioresistance (<xref ref-type="bibr" rid="B5">Chen et al., 2020</xref>). In ESCC, a report has described specifically the pro-metastatic property of LINC00662 (<xref ref-type="bibr" rid="B43">Zhang et al., 2020</xref>), but little was discovered in relation to LINC00662-mediated angiogenesis. miR-195-5p is an anti-angiogenic modulator in human cancers (<xref ref-type="bibr" rid="B3">Cai et al., 2018</xref>; <xref ref-type="bibr" rid="B9">Dai et al., 2019</xref>). In the setting of ESCC, miR-195-5p has been identified as a novel biomarker for cancer diagnosis, classification and prognosis (<xref ref-type="bibr" rid="B17">Li C. Y et al., 2019</xref>), but miR-195-5p-dependent angiogenesis remains unknown. Tumor angiogenesis mainly relies on the response driven by vascular endothelial growth factor A (VEGFA) (<xref ref-type="bibr" rid="B8">Claesson-Welsh and Welsh, 2013</xref>). VEGFA is commonly amplified in esophageal adenocarcinomas (<xref ref-type="bibr" rid="B4">Cancer Genome Atlas Research, Network et al., 2017</xref>) and regulation of VEGFA by miRNAs serves a therapeutic option for EC (<xref ref-type="bibr" rid="B14">Kong et al., 2016</xref>; <xref ref-type="bibr" rid="B31">Shen W et al., 2020</xref>). For reasons of treatments, our research mainly discussed the effect of LINC00662 delivered by ESCC cells-derived EVs on angiogenesis through modification of miR-195-5p and VEGFA.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Methods and Materials</title>
<sec id="s2-1">
<title>Tissue Collection</title>
<p>A total of 84 ESCC patients (44&#x2013;79&#xa0;years old, mean age of 62.02 &#xb1; 9.49&#xa0;years) were recruited from The Second Hospital of Hebei Medical University. Among them, 42 cases were in stage I, 28 cases in stage II, and 14 cases in stage III. All patients underwent tumor resection before chemotherapy. ESCC tissues and adjacent normal tissues were collected and preserved at &#x2212;80&#xb0;C. All patients were pathologically diagnosed as ESCC, and no radiotherapy or chemotherapy before surgery was performed. Patients who died from diseases unrelated to ESCC during the follow-up were excluded (<xref ref-type="bibr" rid="B11">He et al., 2020</xref>).</p>
</sec>
<sec id="s2-2">
<title>Cell Culture and Transfection</title>
<p>Human normal esophageal epithelial cells (HEEC) and ESCC cell lines EC9706, Eca109, TE-13, TE-1 and TTN were provided by China Center for Type Culture Collection (Wuhan, China). Cells (3 &#xd7; 10<sup>5</sup> cells/well) with 80% confluence were subjected to transfection using Lipofectamine 2000 (Invitrogen, CA, United States). Overexpressed (oe)-VEGFA, small interfering RNA (si)-LINC00662, oe-LINC00662, miR-195-5p mimic and their corresponding negative control (NC) were all from GenePharma (Shanghai, China) (<xref ref-type="bibr" rid="B18">Li Z et al., 2019</xref>).</p>
</sec>
<sec id="s2-3">
<title>EVs Collection and Identification</title>
<p>ESCC cells were placed in Roswell Park Memorial Institute (RPMI) 1640 medium containing EVs-free 10% fetal bovine serum (FBS) and cultured for 3 d. Then, the cell supernatant was collected and centrifuged to remove cell debris. The EVs were extracted using Hieff&#x2122; Quick exosome isolation kit (41201ES50, YEASEN, Shanghai, China). The supernatant and exosome separation reagent were added into the Eppendorf (EP) tube with a proportion of 2:1 overnight, and then centrifuged at 100,00&#xa0;g for 1&#x2013;2&#xa0;h and the precipitate was resuspended in phosphate buffered saline (PBS). The EV suspension (30&#xa0;&#x3bc;l) together with an equal volume of radioimmunoprecipitation assay (RIPA) lysis buffer was continuously dissolved in microwave (2 times, 10&#xa0;s/time). Then, the EVs were purified at 4&#xb0;C at 12,000 &#xd7; g for 2&#xa0;min, and the supernatant was retained and stored at &#x2212;80&#xb0;C. Protein quantification of EV was performed by bicinchoninic acid (BCA) kit (Beyotime, Nantong, China).</p>
<p>EVs identification: Transmission electron microscope (TEM; JEM-1010, JEOL, Tokyo, Japan) was adopted to observe EV morphology, tunable resistive pulse sensing (TRPS) to examine concentration and diameter of EVs, and Western blot analysis to test EV markers (CD81 and CD9) and non-marker protein (Calnexin and GM130) (<xref ref-type="bibr" rid="B18">Li Z et al., 2019</xref>).</p>
</sec>
<sec id="s2-4">
<title>EVs Uptake</title>
<p>EVs uptake was monitored using PKH26 fluorescent labeling kit (Sigma-Aldrich, CA, United States). EV sample was diluted in diluent C, and then PKH26 dye was added and kept at room temperature. After 4&#xa0;min incubation avoiding light exposure, the reaction was neutralized by 5% bovine serum albumin. Then, EVs, resuspended in PBS were centrifuged at 100,000&#xa0;g for 70&#xa0;min, and incubated with HUVECs for 4&#xa0;h. Subsequently, HUVECs (ATCC, VA, United States) were fixed with 4% paraformaldehyde, labeled with 4&#x2032;,6-diamidino-2-phenylindole (0.5&#xa0;&#x3bc;g/ml; Invitrogen) and imaged under a confocal microscope (Carl Zeiss, Oberkochen, Germany) (<xref ref-type="bibr" rid="B42">Zhang et al., 2021</xref>).</p>
<p>When HUVECs reached 50&#x2013;60% confluence, they were incubated with dextran 498 (Dx498, 100&#xa0;&#x3bc;g/ml) for 2&#xa0;h to label cell membrane lysosomes, washed with PBS and cultured with complete culture medium for 18&#xa0;h. Finally, HUVECs were incubated with PKH26-labeled EVs for colocalization analysis.</p>
</sec>
<sec id="s2-5">
<title>Co-Culture of HUVECs and EVs</title>
<p>HUVECs were allocated into groups: PBS group (HUVECs without any treatment), EV group (HUVECs co-cultured with EV from ESCC cells), si-NC-EV group (HUVECs co-cultured with EVs from si-NC-modified ESCC cells), si-LINC00662-EV group (HUVECs co-cultured with EVs from si-LINC00662-modified ESCC cells), mimic-NC-EV group (HUVECs co-cultured with EVs from miR-195-5p mimic NC-modified ESCC cells), miR-195-5p mimic-EV group (HUVECs co-cultured with EVs from miR-195-5p mimic-modified ESCC cells), si-NC group (HUVECs transfected with si-NC), si-LINC00662 group (HUVECs transfected with si-LINC00662), oe-NC group (HUVECs transfected with oe-NC), oe-LINC0066 group (HUVECs transfected with oe-LINC0066), miR-195-5p mimic-EV &#x2b; oe-NC group (HUVECs co-cultured with EVs from miR-195-5p mimic-modified ESCC cells and further transfected with oe-NC), miR-195-5p mimic-EV &#x2b; oe-VEGFA (HUVECs co-cultured with EVs from miR-195-5p mimic-modified ESCC cells and further transfected with oe-VEGFA).</p>
</sec>
<sec id="s2-6">
<title>3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) Assay</title>
<p>HUVECs were added with 5&#xa0;mg/ml MTT solution (20&#xa0;&#x3bc;l, Solarbio, Beijing, China), and cell viability was measured after 12, 24, and 36&#xa0;h. Using a microplate spectrophotometer (BioTek Instruments, VT, United States), the absorbance at 570&#xa0;nm was measured (<xref ref-type="bibr" rid="B40">You et al., 2021</xref>).</p>
</sec>
<sec id="s2-7">
<title>Colony Formation Test</title>
<p>HUVECs were cultured in RPMI 1640 medium supplemented with 10% FBS, during which the medium was changed every 48&#xa0;h. After 14&#xa0;d, visible colonies were fixed with ethanol, stained with 0.1% crystal violet and manually counted.</p>
</sec>
<sec id="s2-8">
<title>Angiogenesis Test</title>
<p>Matrigel (BD Biosciences) was spread over 24-well plates at 100&#xa0;ml/well and polymerized. HUVECs (resuspended in FBS-free medium) were transferred to the plates at 1 &#xd7; 10<sup>5</sup> cells/well and cultured for 6&#xa0;h. Angiogenesis quantification was judged by the number of branch points of the formed tube in at least five fields of view (<xref ref-type="bibr" rid="B44">Zhou et al., 2019</xref>).</p>
</sec>
<sec id="s2-9">
<title>Transwell Assay</title>
<p>HUVECs were resuspended in serum-free medium, and the resuspension (1 &#xd7; 10<sup>5</sup> cells/mL, 200&#xa0;&#x3bc;l) was added to the top side of Matrigel-coated Transwell chamber (Matrigel was not used to examine cell migration). RPMI 1640 medium (600&#xa0;&#x3bc;l) containing 20% FBS was dispersed in the basolateral chamber. After 48&#xa0;h of culture, cells were fixed with 4% paraformaldehyde, stained with crystal violet and observed under an optical microscope in five fields of view (<xref ref-type="bibr" rid="B18">Li Z et al., 2019</xref>).</p>
</sec>
<sec id="s2-10">
<title>Dual Luciferase Reporter Gene Assay</title>
<p>LINC00662-Wt, LINC00662-Mut, VEGFA-Wt and VEGFA-Mut were cloned and merged with psiCHECK-2 vector (Promega, WI, United States). Employing Lipofectamine 2,000, the vectors were co-transfected with mimic-NC or miR-195-5p mimic into cells and detected by the dual luciferase reporter gene detection system (Promega) (<xref ref-type="bibr" rid="B23">Liu and Meng, 2020</xref>).</p>
</sec>
<sec id="s2-11">
<title>RNA-Pull Down Assay</title>
<p>Cells were transfected with 50&#xa0;nM biotin-labeled Wt-bio-miR-195-5p and Mut-bio-miR-195-5p for 48&#xa0;h, and subjected to reaction in a specific lysis buffer (Ambion, Texas, United States) for 10&#xa0;min. The lysate was incubated with M-280 streptavidin magnetic beads (Sigma) pre-coated with RNase-free BSA and yeast tRNA (TRNABAK-RO, Sigma). The beads were incubated at 4&#xb0;C for 3&#xa0;h and eluted, and the bound RNA was purified by Trizol, and the LINC00662 enrichment was detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR).</p>
</sec>
<sec id="s2-12">
<title>RIP Assay</title>
<p>The binding of LINC00662/miR-195-5p to AGO2 protein was analyzed by Magna RIP kit (Millipore, United States). Cells were lysed with an equal volume of RIPA Lysis Buffer (P0013B, Beyotime) in an ice bath for 5&#xa0;min and centrifuged at 14,000&#xa0;rpm, 4&#xb0;C for 10&#xa0;min. The magnetic beads (50&#xa0;&#xb5;l) were resuspended in 100&#xa0;&#xb5;l RIP Wash Buffer, and added 5&#xa0;&#xb5;g antibody AGO2 (1:50, Abcam) or IgG (1:100, Abcam). The magnetic bead-antibody complex was resuspended in 900&#xa0;&#xb5;L RIP Wash Buffer and incubated with 100&#xa0;&#x3bc;l cell lysate overnight at 4&#xb0;C. The resulting complex was digested with proteinase K and RNA was extracted for PCR detection.</p>
</sec>
<sec id="s2-13">
<title>RT-qPCR</title>
<p>Total RNA in cells and tissues was extracted by Trizol (Takara, Dalian, China) and expression of miR-195-5p was tested by qRT-PCR with the All-in-One miRNA qRT-PCR Detection Kit (GeneCopoeia) and All-in-One miRNA qPCR Primer (GeneCopoeia). Expression of LINC00662 and VEGFA was determined by qRT-PCR RevertAid First Strand cDNA Synthesis Kit (Fermentas) and SYBR Premix Ex Taq (TaKaRa). Primer sequences (<xref ref-type="sec" rid="s11">Supplementary Table S1</xref>) were synthesized by Genepharma. Target expression was analyzed using ABI 7500 (ABI, CA, United States), and standardized by U6 or glyceraldehyde phosphate dehydrogenase. Determination of gene expression was dependent on 2<sup>&#x2212;&#x394;&#x394;Ct</sup> method (<xref ref-type="bibr" rid="B18">Li Z et al., 2019</xref>).</p>
</sec>
<sec id="s2-14">
<title>Western Blot Assay</title>
<p>Total protein was separated with RIPA lysis buffer (Beyotime) and quantified by BCA kit (Pierce, MA, United States). After separation by 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (Beyotime), the protein sample was electroblotted onto nitrocellulose membrane (HTS112&#xa0;M), covered with 5% skim milk and kept overnight with primary antibodies VEGFA (1:1,000), CD81 (1&#xa0;&#x3bc;g/ml), CD9 (1:1,000), Calnexin (1&#xa0;&#x3bc;g/ml), GM130 (1&#xa0;&#x3bc;g/ml) and GAPDH (1:1,000, all from Abcam). Next, horseradish peroxidase-conjugated secondary antibodies goat anti-mouse IgG (1:5,000) and goat anti-rabbit IgG (1:5,000, both from Abcam) were incubated with the membrane, after which signals were detected using SuperSig-nal-West Pico chemiluminescent substrate (Thermo Fisher Scientific, MA, United States). Data analysis was carried out with Image Lab&#x2122; 3.0 (Bio-Rad, CA, United States) (<xref ref-type="bibr" rid="B32">Sui et al., 2021</xref>).</p>
</sec>
<sec id="s2-15">
<title>Tumor Xenografts in Nude Mice</title>
<p>Eca109 cells (2 &#xd7; 106) were injected subcutaneously into the hind limb of BALB/c nude mice (6&#xa0;weeks old, athymic) for the establishment of the ESCC xenograft model. When the nude mice generated the tumors (100&#xa0;mm<sup>3</sup>), 10&#xa0;&#x3bc;g EVs from ESCC cells that had been transfected with si-NC, si-LINC00662, mimic-NC, miR-195-5p mimic, PBS, and exosome release inhibitor (GW4869, 1&#xa0;mg/kg) were subsequently injected into the center of tumor sites every 2&#xa0;days. Nude mice were euthanized 4&#xa0;weeks later, and the subcutaneous tumors were obtained to calculate tumor volume (maximum diameter &#xd7; vertical diameter<sup>2</sup>/2).</p>
</sec>
<sec id="s2-16">
<title>Statistical Analysis</title>
<p>GraphPad Prism 6.0 (GraphPad Software Inc.) and SPSS 20.0 (IBM, NY, United States) were used for data analysis. Values were expressed as mean &#xb1; standard deviation and compared by <italic>t</italic>-test (two groups) or analysis of variance (multiple groups). <italic>p</italic> &#x3c; 0.05 was statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>High LINC00662 and VEGFA and Low miR-195-5p in Cancer Tissues of Patients With ESCC</title>
<p>LINC00662, miR-195-5p, and VEGFA levels in tissue specimens of 84 patients with ESCC were determined by RT-qPCR, as the results reflecting that LINC00662 and VEGFA were upregulated and miR-195-5p was downregulated in ESCC tissues (<xref ref-type="fig" rid="F1">Figures 1A&#x2013;C</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>High LINC00662 and VEGFA and low miR-195-5p in cancer tissues of patients with ESCC. <bold>(A&#x2013;C)</bold>. RT-qPCR detection of LINC00662, miR-195-5p, VEGFA expression in ESCC tissues and adjacent normal tissues of patients; <bold>(D)</bold> RT-qPCR detection of LINC00662 expression in ESCC patients at different TNM stages; <bold>(E)</bold> RT-qPCR detection of LINC00662 expression in HEEC and ESCC cell lines. &#x2a; <italic>p</italic> &#x3c; 0.05 vs. HEEC cells.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g001.tif"/>
</fig>
<p>ESCC patients were grouped according to TNM staging, and RT-qPCR analysis found higher LINC00662 expression in patients in the late stage than in the early stage (<xref ref-type="fig" rid="F1">Figure 1D</xref>). LINC00662 expression was compared in HEEC and ESCC cell lines (EC9706, Eca109, TE13, TE1 and TTN) by RT-qPCR, and the outcomes indicated that LINC00662 was abundantly expressed in ESCC cell lines (<xref ref-type="fig" rid="F1">Figure 1E</xref>). Because Eca109 had the highest LINC00662 level, it was selected for subsequent experiments.</p>
</sec>
<sec id="s3-2">
<title>Repressive Role of LINC00662 Downregulation in Angiogenesis in ESCC, and Upregulation of LINC00662 has the Opposite Effect</title>
<p>To clarify the effect of LINC00662 on Eca109 angiogenesis <italic>in vitro</italic>, LINC00662 was overexpressed or specifically interfered. RT-qPCR test results showed that oe-LINC00662 effectively promoted LINC00662 expression, while si-LINC00662 down-regulated LINC00662 expression in HUVECs (<xref ref-type="fig" rid="F2">Figure 2A</xref>). As reflected by MTT assay, colony formation assay, Transwell assay and angiogenesis test, downregulated LINC00662 depressed proliferation, invasion, migration and angiogenesis but up-regulated LINC00662 promoted these phenotypes of HUVECs (<xref ref-type="fig" rid="F2">Figures 2B&#x2013;F</xref>). Collectively, LINC00662 downregulation inhibits tumor angiogenesis.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Repressive role of LINC00662 downregulation in angiogenesis. <bold>(A)</bold> RT-qPCR detection of LINC00662 expression in HUVECs after transfection with silenced LINC00662; <bold>(B,C)</bold> Viability and colony formation ability of HUVECs after transfection with silenced LINC00662; <bold>(D,E)</bold> Migration and invasion of HUVECs after transfection with silenced LINC00662; <bold>(F)</bold> Angiogenesis of HUVECs after transfection with silenced LINC00662. &#x2a; <italic>p</italic> &#x3c; 0.05 vs. the oe-NC group; &#x23; <italic>p</italic> &#x3c; 0.05 vs. the si-NC group.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>EVs Collection and Identification</title>
<p>A white precipitate was separated from the culture medium of Eca109 cells by differential centrifugation. Under the TEM, the white precipitate was round or elliptical vesicles with a double-layer membrane structure and a diameter of 40&#x2013;100&#xa0;nm (<xref ref-type="fig" rid="F3">Figure 3A</xref>); TRPS showed that the mode of particle diameter was 90&#xa0;nm and the average diameter was 130&#xa0;nm (<xref ref-type="fig" rid="F3">Figure 3B</xref>); Western blot detected that CD81 and CD9 were both positively expressed whilst calnexin and GM130 were not expressed in these vesicles (<xref ref-type="fig" rid="F3">Figure 3C</xref>), confirming that EVs were extracted successfully.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>EVs collection and identification. <bold>(A)</bold> Morphology and structure of EVs under TEM; <bold>(B)</bold> Concentration and diameter of EVs examined by TRPS; <bold>(C)</bold> EV markers (CD81, CD9, Calnexin and GM130) analyzed by Western blot; <bold>(D)</bold> Distribution of PKH26-labled EVs in HUVECs; <bold>(E)</bold> Co-localization of lysosome and EVs in HUVECs.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g003.tif"/>
</fig>
<p>PKH26-labeled EVs were co-cultured with HUVECs. Observed under a fluorescence microscope, EVs could enter HUVECs, and over time, the more EVs taken up by HUVECs (<xref ref-type="fig" rid="F3">Figure 3D</xref>). Fluorescence colocalization experiment showed that HUVECs incubated with Dx498 were co-cultured with PKH26-labeled EVs, and EVs and lysosomes were colocalized (<xref ref-type="fig" rid="F3">Figure 3E</xref>).</p>
</sec>
<sec id="s3-4">
<title>Anti-Angiogenesis Effect of EVs-Mediated Delivery of Inhibited LINC00662</title>
<p>After co-culture with Eca109 cells-derived EVs, RT-qPCR detection found that LINC00662 expression was increased in HUVECs, while LINC00662 expression was decreased after co-culture with EVs extracted from Eca109 cells transfected with si-LINC00662 (<xref ref-type="fig" rid="F4">Figures 4A,B</xref>). Subsequently, analysis of cell functions revealed that Eca109 cells-derived EVs augmented proliferation, invasion, migration and angiogenesis of HUVECs, while downregulated LINC00662 reversed the effects of Eca109 cells-derived EVs (<xref ref-type="fig" rid="F4">Figures 4C&#x2013;G</xref>). In conclusion, Eca109 cells-derived EVs transfer of silenced LINC00662 blocks angiogenesis.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Anti-angiogenesis effect of EVs transfer of inhibited LINC00662. <bold>(A,B)</bold> RT-qPCR detection of LINC00662 expression in HUVECs after co-culture with EVs; <bold>(C,D)</bold> Viability and colony formation ability of HUVECs after co-culture with EVs; <bold>(E,F)</bold> Migration and invasion of HUVECs after co-culture with EVs; <bold>(G)</bold> Angiogenesis of HUVECs after co-culture with EVs. &#x2a; <italic>p</italic> &#x3c; 0.05 vs. the PBS group; &#x23;<italic>p</italic> &#x3c; 0.05 vs. the si-NC-EV group.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g004.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Anti-Angiogenic Role of EVs Carrying Upregulated miR-195-5p</title>
<p>RT-qPCR test measured that co-culture with EVa from miR-195-5p mimic-treated Eca109 cells augmented miR-195-5p expression in HUVECs (<xref ref-type="fig" rid="F5">Figure 5A</xref>). As a result of miR-195-5p upregulation, Eca109 cells-derived EVs-induced aggressive behaviors and angiogenesis of HUVECs were all constrained (<xref ref-type="fig" rid="F5">Figures 5B&#x2013;F</xref>). In short, EVa transfer of upregulated miR-195-5p exerts anti-angiogenic effect.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Anti-angiogenic role of EVs expressing upregulated miR-195-5p. <bold>(A)</bold> RT-qPCR detection of miR-195-5p expression in HUVECs after co-culture with EVs; <bold>(B,C)</bold> Viability and colony formation ability of HUVECs after co-culture with EVs; <bold>(D,E)</bold> Migration and invasion of HUVECs after co-culture with EVs; <bold>(F)</bold> Angiogenesis of HUVECs after co-culture with EVs. &#x2a; <italic>p</italic> &#x3c; 0.05 vs. the mimic-NC-EV group.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Binding Relation Between LINC00662 and miR-195-5p; Targeting Relation Between miR-195-5p and VEGFA</title>
<p>On the bioinformatics website, a binding relationship was predicted between LINC00662 and miR-195-5p (<xref ref-type="fig" rid="F6">Figure 6A</xref>), as well as miR-195-5p and VEGFA mRNA (<xref ref-type="fig" rid="F6">Figure 6B</xref>). Using dual luciferase reporter assay, it was estimated that miR-195-5p mimic reduced the luciferase activity of LINC00662-Wt and that of VEGFA-Wt (<xref ref-type="fig" rid="F6">Figures 6C,D</xref>). RNA-pull down assay showed that Mut-bio-miR-195-5p had no significant effect on LINC00662 enrichment and Wt-bio-miR-195-5p could increase the amount of LINC00662 enrichment (<xref ref-type="fig" rid="F6">Figure 6E</xref>). RIP experiment suggested an elevation in Ago2-bound LINC00662, indicating that LINC00662 could directly bind with miR-195-5p (<xref ref-type="fig" rid="F6">Figure 6F</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Binding relation between LINC00662 and miR-195-5p; targeting relation between miR-195-5p and VEGFA. <bold>(A,B)</bold> Binding sites of LINC00662 and miR-195-5p, miR-195-5p and VEGFA; <bold>(C,D)</bold> Dual luciferase report results; <bold>(E)</bold> RNA pull-down test detected the enrichment of LINC00662; <bold>(F)</bold> RIP detected the binding of LINC00662 and miR-195-5p to AGO2; <bold>(G)</bold> RT-qPCR detection of miR-195&#x2013;5p expression in HUVECs after co-culture with EVs; <bold>(H,I)</bold> RT-qPCR and Western blot analysis of VEGFA mRNA and protein expression in HUVECs after co-culture with EVs.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g006.tif"/>
</fig>
<p>Alternations of gene expression were observed: EVs delivery of silenced LINC00662 elevated miR-195-5p expression in HUVECs (<xref ref-type="fig" rid="F6">Figure 6G</xref>) while that of upregulated miR-195-5p lowered VEGFA levels (<xref ref-type="fig" rid="F6">Figures 6H,I</xref>).</p>
</sec>
<sec id="s3-7">
<title>Reversal of miR-195-5p-Mediated Effects on HUVECs by Overexpressed VEGFA</title>
<p>miR-195-5p/VEGFA axis-induced function for HUVECs was further evaluated. After co-culture with EVs carrying upregulated miR-195-5p, HUVECs were transfected with oe-VEGFA, which successfully elevated VEGFA expression (<xref ref-type="fig" rid="F7">Figures 7A,B</xref>). Overexpression of VEGFA reversed the effects of EVs carrying upregulated miR-195-5p on proliferation, invasion, migration and angiogenesis of HUVECs (<xref ref-type="fig" rid="F7">Figures 7C&#x2013;G</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Reversal of miR-195-5p-mediated effects on HUVECs by overexpressed VEGFA. <bold>(A,B)</bold> RT-qPCR and Western blot analysis of VEGFA expression in HUVECs after co-culture with EVs and transfection with overexpressed VEGFA; <bold>(C,D)</bold> Viability and colony formation ability of HUVECs after co-culture with EVs and transfection with overexpressed VEGFA; <bold>(E,F)</bold> Migration and invasion of HUVECs after co-culture with EVs and transfection with overexpressed VEGFA; <bold>(G)</bold> Angiogenesis of HUVECs after co-culture with EVs and transfection with overexpressed VEGFA. &#x2a; <italic>p</italic> &#x3c; 0.05 vs. the miR-195-5p mimic-EV &#x2b; oe-NC group.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g007.tif"/>
</fig>
</sec>
<sec id="s3-8">
<title>Tumor Suppression Effect of EVs Carrying Downregulated LINC00662 or Upregulated miR-195-5p in Mice</title>
<p>To further determine the angiogenic role of EVs in vivo, an ESCC tumor-bearing nude mice model was established and treated with EVs. In mice xenograft model, after treatment with EVs delivering depleted LINC00662 or restored miR-195-5p, tumors grew slowly, accompanied by smaller tumor volume and lighter tumor weight (<xref ref-type="fig" rid="F8">Figures 8A&#x2013;C</xref>). Furthermore, the effect of EV-specific inhibitor GW4869 on the growth of nude mice was observed, reflecting that GW4869 treatment had a better efficacy to repress tumor growth (<xref ref-type="fig" rid="F8">Figures 8D&#x2013;F</xref>). Simply, LINC00662 suppression or miR-195-5p overexpression inhibits the growth of tumor.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Tumor suppression effect of EVs expressing downregulated LINC00662 or upregulated miR-195-5p. <bold>(A,D)</bold> Tumor volume changes in nude mice; <bold>(B,E)</bold>. Representative tumors in nude mice; <bold>(C,F)</bold> Tumor weight in nude mice. &#x2a; <italic>p</italic> &#x3c; 0.05 vs. the si-NC-EV; &#x23;<italic>p</italic> &#x3c; 0.05 vs. the mimic-NC-EV group; &#x0026; <italic>p</italic> &#x3c; 0.05 vs. the PBS group.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g008.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In the tumor microenvironment in EC, induction of angiogenesis is pro-tumorigenic, and its management is critical to the development of anti-angiogenic therapy (<xref ref-type="bibr" rid="B1">Barzi and Lenz, 2012</xref>; <xref ref-type="bibr" rid="B20">Lin et al., 2016</xref>). In the present article, it was clearly described that silenced LINC00662 transfer by ESCC cells-derived EVs attenuates angiogenesis by miR-195-5p-dependent VEGFA downregulation (<xref ref-type="fig" rid="F9">Figure 9</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>ESCC cells-derived EVs transferal of up-regulation of LINC00662 to promote angiogenesis in esophageal cancer by downregulating miR-195-5p and upregulating VEGFA.</p>
</caption>
<graphic xlink:href="fbioe-10-772514-g009.tif"/>
</fig>
<p>To begin with, LINC00662 expression was found to be heightened in cancer tissues of patients with ESCC and was associated with advanced TNM stage. Consistently, LINC00662 high expression has been examined in cancer tissues of patients with colorectal cancer, indicating a positive correlation with tumor T stage (<xref ref-type="bibr" rid="B35">Wang et al., 2019</xref>). Elevation of LINC00662 has also been measured in patients with ESCC, which is negatively correlated with patients&#x2019; clinical outcome (<xref ref-type="bibr" rid="B43">Zhang et al., 2020</xref>). For HUVECs, knocking down LINC00662 made relives of proliferation, invasion, migration and tube formation abilities, confirming that LINC00662 silencing possesses anti-angiogenic effect. Bo Cheng <italic>et al.</italic> have displayed that LINC00662 overexpression increases proliferation, invasion and migration of colon cancer cells <italic>in vitro</italic> and tumor growth <italic>in vivo</italic> (<xref ref-type="bibr" rid="B6">Cheng B et al., 2020</xref>). In addition, a report by Long Cheng <italic>et al.</italic> has implicated the inhibitory role of LINC00662 knockdown as to proliferation, migration and invasion of breast cancer cells (<xref ref-type="bibr" rid="B7">Cheng L et al., 2020</xref>). At present, very few analysis has evaluated the complete mechanism of LINC00662-mediated angiogenesis.</p>
<p>Afterwards, ESCC cells-derived EVs were found to augment angiogenesis, but inhibited LINC00662, effectively transported by EVs could attenuate angiogenesis <italic>in vitro</italic> and tumor formation <italic>in vivo</italic>. In the light of an article composed by Yu Mao <italic>et al.</italic>, ESCC cells-secreted EVs under hypoxia stimulate angiogenesis by inducing HUVECs to proliferate, invade, migrate and form tubes <italic>in vitro</italic> (<xref ref-type="bibr" rid="B25">Mao et al., 2019</xref>). In addition to EVs from ESCC cells, EVs from other cancer cells present pivotal actions in angiogenesis. As exampled by a late paper, EVs secreted by hypoxic papillary thyroid cancer cells enhance endothelial tube formation (<xref ref-type="bibr" rid="B37">Wu et al., 2019</xref>). On the other hand, EVs extracted from gastric cancer cells could be internalized by vascular endothelial cells, so as to activate angiogenesis and tumor growth (<xref ref-type="bibr" rid="B38">Yang et al., 2018</xref>). Nils Ludwig <italic>et al.</italic> have experimentally observed that after internalization of EVs from head and neck squamous cell carcinoma cells by HUVECs, proliferation, migration and tube formation of HUVECs are all promoted (<xref ref-type="bibr" rid="B24">Ludwig et al., 2018</xref>). Remarkably, hypoxia-induced EVs from lung cancer cells cause formidable force in accelerating proliferation and tube-forming abilities of HUVECs (<xref ref-type="bibr" rid="B27">Mo et al., 2020</xref>).</p>
<p>Subsequently, miR-195-5p, as a downstream actor of LINC00662, attracted our attention. Gene expression measurement found lowly expressed miR-195-5p in ESCC tissues, showing consistency with a former article (<xref ref-type="bibr" rid="B30">Shen S et al., 2020</xref>). Next, experimental assays proved that EVs delivery of restored miR-195-5p reduced angiogenesis <italic>in vitro</italic> and tumor growth <italic>in vivo</italic>. Indeed, much efforts have been paid to disclose the anti-angiogenic function of miR-195-5p in cancers, including squamous cell lung cancer cells (<xref ref-type="bibr" rid="B22">Liu et al., 2019</xref>), ovarian cancer (<xref ref-type="bibr" rid="B9">Dai et al., 2019</xref>) and prostate cancer (<xref ref-type="bibr" rid="B3">Cai et al., 2018</xref>).</p>
<p>It is of interest that miR-195-5p could directly inhibit VEGFA (<xref ref-type="bibr" rid="B26">Maroof et al., 2019</xref>), and the finding was echoed with our research. Importantly, data analysis further proved that VEGFA overexpression reversed miR-195-5p-dependent inhibition of angiogenesis. Based on the observation of Ruoqin W <italic>et al.</italic>, the conditioned medium of CRC cells enhances migration, invasion, and tube formation of HUVECs, which could be reversed by VEGFA silencing (<xref ref-type="bibr" rid="B36">Wang et al., 2020</xref>). Meanwhile, Lijun L <italic>et al.</italic> have elaborated that in the treatment of non-small cell lung cancer with anlotinib, suppressed VEGFA signal facilitates to restrain the activities of HUVECs (<xref ref-type="bibr" rid="B19">Liang et al., 2019</xref>). Accordingly, it has been established that VEGFA overexpression can eliminate the anti-angiogenic effect induced by miR-130&#xa0;b in prostate cancer (<xref ref-type="bibr" rid="B28">Mu et al., 2020</xref>).</p>
<p>Overall, our study analysis obtained that ESCC cells-derived EVs transferal of downregulated LINC00662 decreases miR-195-5p-targeted VEGFA and relives angiogenesis induction. This research helps the development of potential molecule-targeted therapy for angiogenesis in tumor progression.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>All patients signed an informed consent form. All animal experiments adhered to the protocol of Animal Protection and Use Committee in The Second Hospital of Hebei Medical University.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>SL finished study design, FL, RN, and HZ&#x7c; finished experimental studies, SG, ZD, and HZ finished data analysis, FZ, ZD, and SL finished manuscript editing. All authors read and approved the final manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This study was supported by The Natural Science Fundation of Hebei Province (Grant No. H2018206249).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fbioe.2022.772514/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fbioe.2022.772514/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barzi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lenz</surname>
<given-names>H.-J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Angiogenesis-related Agents in Esophageal Cancer</article-title>. <source>Expert Opin. Biol. Ther.</source> <volume>12</volume> (<issue>10</issue>), <fpage>1335</fpage>&#x2013;<lpage>1345</lpage>. <pub-id pub-id-type="doi">10.1517/14712598.2012.707180</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>G. K.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Are</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Managing Squamous Cell Esophageal Cancer</article-title>. <source>Surg. Clin. North America</source> <volume>99</volume> (<issue>3</issue>), <fpage>529</fpage>&#x2013;<lpage>541</lpage>. <pub-id pub-id-type="doi">10.1016/j.suc.2019.02.006</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>miR-195 Inhibits Cell Proliferation and Angiogenesis in Human Prostate Cancer by Downregulating PRR11 Expression</article-title>. <source>Oncol. Rep.</source> <volume>39</volume> (<issue>4</issue>), <fpage>1658</fpage>&#x2013;<lpage>1670</lpage>. <pub-id pub-id-type="doi">10.3892/or.2018.6240</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<collab>Cancer Genome Atlas Research, Network</collab>
<collab>Analysis Working Group: Asan University</collab>
<collab>B.C.Cancer Agency</collab>
<collab>Brigham and Women&#x2019;s Hospital</collab>
<collab>Broad Institute</collab>
<collab>Brown University</collab>
<person-group person-group-type="author">
<etal/>
</person-group> (<year>2017</year>). <article-title>Integrated Genomic Characterization of Oesophageal Carcinoma</article-title>. <source>Nature</source> <volume>541</volume> (<issue>7636</issue>), <fpage>169</fpage>&#x2013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1038/nature20805</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Knockdown of LINC00662 Represses AK4 and Attenuates Radioresistance of Oral Squamous Cell Carcinoma</article-title>. <source>Cancer Cel Int</source> <volume>20</volume>, <fpage>244</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-020-01286-9</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rong</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>LncRNA LINC00662 Promotes colon Cancer Tumor Growth and Metastasis by Competitively Binding with miR-340-5p to Regulate CLDN8/IL22 Co-expression and Activating ERK Signaling Pathway</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>39</volume> (<issue>1</issue>), <fpage>5</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-019-1510-7</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Long Non-coding RNA LINC00662 Promotes Proliferation and Migration of Breast Cancer Cells via Regulating the miR-497-5p/EglN2 axis</article-title>. <source>Acta Biochim. Pol.</source> <volume>67</volume> (<issue>2</issue>), <fpage>229</fpage>&#x2013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.18388/abp.2020_5203</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claesson-Welsh</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Welsh</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>VEGFA and Tumour Angiogenesis</article-title>. <source>J. Intern. Med.</source> <volume>273</volume> (<issue>2</issue>), <fpage>114</fpage>&#x2013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1111/joim.12019</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Overexpression of microRNA-195-5p Reduces Cisplatin Resistance and Angiogenesis in Ovarian Cancer by Inhibiting the PSAT1-dependent GSK3&#x3b2;/&#x3b2;-Catenin Signaling Pathway</article-title>. <source>J. Transl Med.</source> <volume>17</volume> (<issue>1</issue>), <fpage>190</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-019-1932-1</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Ovarian Cancer Cell-Secreted Exosomal miR-205 Promotes Metastasis by Inducing Angiogenesis</article-title>. <source>Theranostics</source> <volume>9</volume> (<issue>26</issue>), <fpage>8206</fpage>&#x2013;<lpage>8220</lpage>. <pub-id pub-id-type="doi">10.7150/thno.37455</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Human Umbilical Cord Mesenchymal Stem Cells-Derived Exosomes Deliver microRNA-375 to Downregulate ENAH and Thus Retard Esophageal Squamous Cell Carcinoma Progression</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>39</volume> (<issue>1</issue>), <fpage>140</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-020-01631-w</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Systemic Treatment of Advanced Esophageal Squamous Cell Carcinoma: Chemotherapy, Molecular-Targeting Therapy and Immunotherapy</article-title>. <source>Jpn. J. Clin. Oncol.</source> <volume>49</volume> (<issue>5</issue>), <fpage>412</fpage>&#x2013;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1093/jjco/hyz034</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knox</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bece</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bucci</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>P. H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A Clinician&#x27;s Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <fpage>1612</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01612</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>The Crucial Role of miR-126 on Suppressing Progression of Esophageal Cancer by Targeting VEGF-A</article-title>. <source>Cell Mol Biol Lett</source> <volume>21</volume>, <fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/s11658-016-0004-2</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lam</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Introduction: Esophageal Squamous Cell Carcinoma-Current Status and Future Advances</article-title>. <source>Methods Mol. Biol.</source> <volume>2129</volume>, <fpage>1</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-0716-0377-2_1</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname>
<given-names>H.-L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G.-W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kuang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Glioma Cells Enhance Angiogenesis and Inhibit Endothelial Cell Apoptosis through the Release of Exosomes that Contain Long Non-coding RNA CCAT2</article-title>. <source>Oncol. Rep.</source> <volume>38</volume> (<issue>2</issue>), <fpage>785</fpage>&#x2013;<lpage>798</lpage>. <pub-id pub-id-type="doi">10.3892/or.2017.5742</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.-W.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.-H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.-L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Identification of microRNAs as Novel Biomarkers for Esophageal Squamous Cell Carcinomaa: A Study Based on the Cancer Genome Atlas (Tcga) and Bioinformatics</article-title>. <source>Chin. Med. J. (Engl)</source> <volume>132</volume> (<issue>18</issue>), <fpage>2213</fpage>&#x2013;<lpage>2222</lpage>. <pub-id pub-id-type="doi">10.1097/cm9.0000000000000427</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Exosomal lncRNA ZFAS1 Regulates Esophageal Squamous Cell Carcinoma Cell Proliferation, Invasion, Migration and Apoptosis via microRNA-124/STAT3 axis</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>38</volume> (<issue>1</issue>), <fpage>477</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-019-1473-8</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Autophagy Inhibition Potentiates the Anti-angiogenic Property of Multikinase Inhibitor Anlotinib through JAK2/STAT3/VEGFA Signaling in Non-small Cell Lung Cancer Cells</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>38</volume> (<issue>1</issue>), <fpage>71</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-019-1093-3</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>E. W.</given-names>
</name>
<name>
<surname>Karakasheva</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Hicks</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Bass</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Rustgi</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The Tumor Microenvironment in Esophageal Cancer</article-title>. <source>Oncogene</source> <volume>35</volume> (<issue>41</issue>), <fpage>5337</fpage>&#x2013;<lpage>5349</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2016.34</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The Research Advances of Exosomes in Esophageal Cancer</article-title>. <source>Biomarkers Med.</source> <volume>13</volume> (<issue>8</issue>), <fpage>685</fpage>&#x2013;<lpage>695</lpage>. <pub-id pub-id-type="doi">10.2217/bmm-2018-0314</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>miR-195 S-uppresses M-etastasis and A-ngiogenesis of S-quamous C-ell L-ung C-ancer by I-nhibiting the E-xpression of VEGF</article-title>. <source>Mol. Med. Rep.</source> <volume>20</volume> (<issue>3</issue>), <fpage>2625</fpage>&#x2013;<lpage>2632</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2019.10496</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>LINC00662 Long Non-coding RNA Knockdown Attenuates the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Regulating the microRNA-15a-5p/Notch2 Axis</article-title>. <source>Ott</source> <volume>13</volume>, <fpage>7517</fpage>&#x2013;<lpage>7530</lpage>. <pub-id pub-id-type="doi">10.2147/ott.s256464</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ludwig</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yerneni</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Razzo</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Whiteside</surname>
<given-names>T. L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells</article-title>. <source>Mol. Cancer Res.</source> <volume>16</volume> (<issue>11</issue>), <fpage>1798</fpage>&#x2013;<lpage>1808</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.mcr-18-0358</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Hypoxic Exosomes Facilitate Angiogenesis and Metastasis in Esophageal Squamous Cell Carcinoma through Altering the Phenotype and Transcriptome of Endothelial Cells</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>38</volume> (<issue>1</issue>), <fpage>389</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-019-1384-8</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maroof</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Irani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Arianna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vider</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gopalan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>A. K.-y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Interactions of Vascular Endothelial Growth Factor and P53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers</article-title>. <source>Ccdt</source> <volume>19</volume> (<issue>7</issue>), <fpage>561</fpage>&#x2013;<lpage>570</lpage>. <pub-id pub-id-type="doi">10.2174/1568009618666180628154727</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Effects of Hypoxia and Radiation-Induced Exosomes on Migration of Lung Cancer Cells and Angiogenesis of Umbilical Vein Endothelial Cells</article-title>. <source>Radiat. Res.</source> <volume>194</volume> (<issue>1</issue>), <fpage>71</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1667/rr15555.1</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu</surname>
<given-names>H. Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S. B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Nan</surname>
<given-names>C. J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>MiR-130b/TNF-&#x3b1;/NF-&#x3ba;B/VEGFA Loop Inhibits Prostate Cancer Angiogenesis</article-title>. <source>Clin. Transl Oncol.</source> <volume>22</volume> (<issue>1</issue>), <fpage>111</fpage>&#x2013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1007/s12094-019-02217-5</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reichenbach</surname>
<given-names>Z. W.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Saxena</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Farkas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Karassik</surname>
<given-names>E. G.</given-names>
</name>
<name>
<surname>Klochkova</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Clinical and Translational Advances in Esophageal Squamous Cell Carcinoma</article-title>. <source>Adv. Cancer Res.</source> <volume>144</volume>, <fpage>95</fpage>&#x2013;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1016/bs.acr.2019.05.004</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen S</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Silencing lncRNA AGAP2-AS1 Upregulates miR-195-5p to Repress Migration and Invasion of EC Cells via the Decrease of FOSL1 Expression</article-title>. <source>Mol. Ther. - Nucleic Acids</source> <volume>20</volume>, <fpage>331</fpage>&#x2013;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtn.2019.12.036</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen W</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Silencing lncRNA AFAP1-AS1 Inhibits the Progression of Esophageal Squamous Cell Carcinoma Cells via Regulating the miR-498/VEGFA Axis</article-title>. <source>Cmar</source> <volume>12</volume>, <fpage>6397</fpage>&#x2013;<lpage>6409</lpage>. <pub-id pub-id-type="doi">10.2147/cmar.s254302</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sui</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>LncRNA MEG8 Attenuates Cerebral Ischemia after Ischemic Stroke through Targeting miR-130a-5p/VEGFA Signaling</article-title>. <source>Cell Mol Neurobiol</source> <volume>41</volume> (<issue>6</issue>), <fpage>1311</fpage>&#x2013;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1007/s10571-020-00904-4</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Th&#xe9;ry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Witwer</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Aikawa</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alcaraz</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Andriantsitohaina</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): a Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines</article-title>. <source>J. Extracell Vesicles</source> <volume>7</volume> (<issue>1</issue>), <fpage>1535750</fpage>. <pub-id pub-id-type="doi">10.1080/20013078.2018.1535750</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viallard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Larriv&#xe9;e</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Tumor Angiogenesis and Vascular Normalization: Alternative Therapeutic Targets</article-title>. <source>Angiogenesis</source> <volume>20</volume> (<issue>4</issue>), <fpage>409</fpage>&#x2013;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1007/s10456-017-9562-9</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Linc00662 Promotes Tumorigenesis and Progression by Regulating miR-497-5p/AVL9 Axis in Colorectal Cancer</article-title>. <source>Front. Genet.</source> <volume>10</volume>, <fpage>1385</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2019.01385</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>B7-H3 Promotes Colorectal Cancer Angiogenesis through Activating the NF-&#x39a;b Pathway to Induce VEGFA Expression</article-title>. <source>Cell Death Dis</source> <volume>11</volume> (<issue>1</issue>), <fpage>55</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-020-2252-3</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>R.-R.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>J.-Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Exosomes Increased Angiogenesis in Papillary Thyroid Cancer Microenvironment</article-title>. <source>Endocr. Relat. Cancer</source> <volume>26</volume> (<issue>5</issue>), <fpage>525</fpage>&#x2013;<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1530/erc-19-0008</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Exosome-Derived miR-130a Activates Angiogenesis in Gastric Cancer by Targeting C-MYB in Vascular Endothelial Cells</article-title>. <source>Mol. Ther.</source> <volume>26</volume> (<issue>10</issue>), <fpage>2466</fpage>&#x2013;<lpage>2475</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2018.07.023</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname>
<given-names>L.-N.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>Q.-W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>W.-J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Exosomal LINC00161 Promotes Angiogenesis and Metastasis via Regulating miR-590-3p/ROCK axis in Hepatocellular Carcinoma</article-title>. <source>Cancer Gene Ther.</source> <volume>28</volume> (<issue>6</issue>), <fpage>719</fpage>&#x2013;<lpage>736</lpage>. <pub-id pub-id-type="doi">10.1038/s41417-020-00269-2</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Cancer-derived Exosomal miR-25-3p Promotes Pre-metastatic Niche Formation by Inducing Vascular Permeability and Angiogenesis</article-title>. <source>Nat. Commun.</source> <volume>9</volume> (<issue>1</issue>), <fpage>5395</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-07810-w</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Exosomes from microRNA&#x2010;126 Overexpressing Mesenchymal Stem Cells Promote Angiogenesis by Targeting the PIK3R2&#x2010;mediated PI3K/Akt Signalling Pathway</article-title>. <source>J. Cel Mol Med</source> <volume>25</volume> (<issue>4</issue>), <fpage>2148</fpage>&#x2013;<lpage>2162</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.16192</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>LINC00662 Promotes Cell Viability and Metastasis in Esophageal Squamous Cell Carcinoma by Sponging miR &#x2010;340&#x2010;5p and Upregulating HOXB2</article-title>. <source>Thorac. Cancer</source> <volume>11</volume> (<issue>8</issue>), <fpage>2306</fpage>&#x2013;<lpage>2315</lpage>. <pub-id pub-id-type="doi">10.1111/1759-7714.13551</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Exosomes Carrying MicroRNA-155 Target Forkhead Box O3 of Endothelial Cells and Promote Angiogenesis in Gastric Cancer</article-title>. <source>Mol. Ther. - Oncolytics</source> <volume>15</volume>, <fpage>223</fpage>&#x2013;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1016/j.omto.2019.10.006</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>